RecruitingNCT05089747
CIRculating CANcer MAster-Protocol
MAster Protocol Studying the Impact of Blood Biopsy on Screening, Diagnosis, Diagnostic and Follow-up of Solid Cancer in Adult
Sponsor
Hospices Civils de Lyon
Enrollment
6,000 participants
Start Date
Dec 5, 2022
Study Type
OBSERVATIONAL
Conditions
Summary
This exploratory study will focus on the development of the analyses of blood biomarkers to better understand the circulating biomarkers associated with cancer diagnosis, treatment efficacy and progressive disease
Eligibility
Min Age: 18 Years
Inclusion Criteria5
- Adult (>18y)
- Owing a social security insurance
- Any solid cancer diagnosed by histopathology or cytology
- Patient with blood sampling required as per standard of care
- Informed consent signed
Exclusion Criteria5
- Refusal to participate
- No blood sampling required as per standard of care
- Hemoglobin < 7g/dl (< 9g/dl if respiratory or cardiovascular disease history)
- Heterologous blood transfusion in the last 48 hours
- Weight under 20 kg
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
BIOLOGICALBlood sampling for biomarker analysis (microRNA, circulating DNA…)
From one to four blood samplings: at diagnosis, after the first cycle of treatment, end of treatment, progressive disease (or end of study).
Locations(7)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05089747